IL-17A in Psoriasis Knowledge Centre

Welcome to the IL-17A in Psoriasis Knowledge Centre.

This site focuses on the inflammatory cytokine, IL-17A, its key role in the pathogenesis of psoriasis and the IL-17 pathway itself as a target for therapeutic intervention.

The core of information is supplemented by videos from leading experts, clinical presentations, content from international congresses, key publications and links to useful external resources.

Highlights include a series of Interactive Publications on Secukinamab – a new feature for viewing current papers. 

Latest content:

IL-17 Pathway - Mechanistic Video

Interactive Publications

Clinical Education
Each interactive publication includes the full text of a clinical paper about IL-17A inhibition in psoriasis. Within each interactive publication, information is organised into sections and tiered to allow the study to be reviewed quickly or explored in depth. Illustrated infographics highlight key data and concepts throughout. Current publications include: 'Safety of Secukinumab in the Treatment of Psoriasis', 'Secukinumab in Plaque Psoriasis - Results of two Phase 3 Trials', (Langley et al., 2014) and 'Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)', (Mrowietz et al., 2015).
View

Featured website

Secukinumab clinical trial data